Cargando…
Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia
BACKGROUND: Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describ...
Autores principales: | Bertrand, Elisabeth, Jouy, Nathalie, Manier, Salomon, Fouquet, Guillemette, Guidez, Stéphanie, Boyle, Eileen, Noel, Stéphanie, Tomowiak, Cécile, Herbaux, Charles, Schraen, Susanna, Preudhomme, Claude, Quesnel, Bruno, Poulain, Stéphanie, Leleu, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762562/ https://www.ncbi.nlm.nih.gov/pubmed/29348877 http://dx.doi.org/10.18632/oncotarget.22872 |
Ejemplares similares
-
BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
por: Herbaux, Charles, et al.
Publicado: (2016) -
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022) -
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia
por: Gaudette, Brian T., et al.
Publicado: (2015) -
Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)